Schulzke Sven M, Rao Shripada, Patole Sanjay K
Department of Neonatal Paediatrics, Women's and Children's Health Service, Perth, Australia.
BMC Pediatr. 2007 Sep 5;7:30. doi: 10.1186/1471-2431-7-30.
The objective of this study was to systematically review randomized trials assessing therapeutic hypothermia as a treatment for term neonates with hypoxic ischemic encephalopathy.
The Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, CINAHL databases, reference lists of identified studies, and proceedings of the Pediatric Academic Societies were searched in July 2006. Randomized trials assessing the effect of therapeutic hypothermia by either selective head cooling or whole body cooling in term neonates were eligible for inclusion in the meta-analysis. The primary outcome was death or neurodevelopmental disability at >or= 18 months.
Five trials involving 552 neonates were included in the analysis. Cooling techniques and the definition and severity of neurodevelopmental disability differed between studies. Overall, there is evidence of a significant effect of therapeutic hypothermia on the primary composite outcome of death or disability (RR: 0.78, 95% CI: 0.66, 0.92, NNT: 8, 95% CI: 5, 20) as well as on the single outcomes of mortality (RR: 0.75, 95% CI: 0.59, 0.96) and neurodevelopmental disability at 18 to 22 months (RR: 0.72, 95% CI: 0.53, 0.98). Adverse effects include benign sinus bradycardia (RR: 7.42, 95% CI: 2.52, 21.87) and thrombocytopenia (RR: 1.47, 95% CI: 1.07, 2.03, NNH: 8) without deleterious consequences.
In general, therapeutic hypothermia seems to have a beneficial effect on the outcome of term neonates with moderate to severe hypoxic ischemic encephalopathy. Despite the methodological differences between trials, wide confidence intervals, and the lack of follow-up data beyond the second year of life, the consistency of the results is encouraging. Further research is necessary to minimize the uncertainty regarding efficacy and safety of any specific technique of cooling for any specific population.
本研究的目的是系统评价评估亚低温治疗足月儿缺氧缺血性脑病疗效的随机试验。
2006年7月检索了Cochrane对照试验中心注册库、MEDLINE、EMBASE、CINAHL数据库、纳入研究的参考文献列表以及儿科学术协会会议记录。评估选择性头部降温或全身降温的亚低温治疗对足月儿疗效的随机试验符合纳入荟萃分析的条件。主要结局为18个月及以上时的死亡或神经发育残疾。
5项涉及552例新生儿的试验纳入分析。各研究间的降温技术以及神经发育残疾的定义和严重程度有所不同。总体而言,有证据表明亚低温治疗对死亡或残疾这一主要复合结局有显著疗效(相对危险度:0.78,95%可信区间:0.66,0.92,需治疗人数:8,95%可信区间:5,20),对死亡率(相对危险度:0.75,95%可信区间:0.59,0.96)以及18至22个月时的神经发育残疾(相对危险度:0.72,95%可信区间:0.53,0.98)这些单一结局也有显著疗效。不良反应包括良性窦性心动过缓(相对危险度:7.42,95%可信区间:2.52,21.87)和血小板减少症(相对危险度:1.47,95%可信区间:1.07,2.03,需治疗的有害事件数:8),但无有害后果。
总体而言,亚低温治疗似乎对中度至重度缺氧缺血性脑病足月儿的结局有益。尽管各试验存在方法学差异、可信区间较宽且缺乏生命第二年以后的随访数据,但结果的一致性令人鼓舞。有必要进一步开展研究,以尽量减少任何特定降温技术对任何特定人群疗效和安全性方面的不确定性。